Product
Supplier
Encyclopedia
Inquiry
Home > Biochemical Engineering > Polypeptide > Tirzepatide for Sale > API Weight loss product: Tirzepatide raw powder,Door-to-Door Delivery
API Weight loss product: Tirzepatide raw powder,Door-to-Door Delivery buy - large image1
API Weight loss product: Tirzepatide raw powder,Door-to-Door Delivery buy - image1

API Weight loss product: Tirzepatide raw powder,Door-to-Door Delivery

2097 Inquiries

Unit Price: Get Latest Price
CAS No.:

2023788-19-2

Grade:

Pharmaceutical Grade

Content:

99%

Port:

shen zhen

Brand:

KY

Packaging:

5mg/10vials;10mg/10vials;20mf/10vials;30mg/10vials

Price valid (until):

2026-05-03

Company Type:
Trader
Location:
China
Payment Terms:
100% TT in advance
Average Lead Time:
1 days
Qualification:
Main Products:

Semaglutide,Retatrutide,Nad+,Tirzepatide

  • Product Description

  • Seller Information

  • Inquiry History

  • Description


      Product Detail 

     Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes. Tirzepatide (LY3298176) shows significantly better efficacy with regard to glucose control and weight loss than do Dulaglutide.

           Tirzepatide is important in maintaining health andregulating gene expression related to aging in various species. age, the levels of NAD+ in people's bodies drop significantly. Studies have highlighted that this decline is associated with a range of age-related diseases, such as accelerated aging, metabolic disorders, heart disease, and neurodegeneration.



     Tirzepatide  has been shown to help lose weight in overweight patients. 

          Tirzepatide is a novel dual glucose -dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) developed by Eli Lilly and Company. Approved by the U.S. FDA in May 2022 under the brand name "Tirzepatide", it is primarily indicated for the treatment of type 2 diabetes mellitus.

          Tirzepatide represents a breakthrough in diabetes management by uniquely targeting both GIP and GLP-1 receptors, which enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety. This dual mechanism offers superior glycemic control and weight loss compared to traditional GLP-1 agonists like semaglutide.

           Tirzepatide’s most common side effects include gastrointestinal issues such as nausea, diarrhea, and vomiting, which typically diminish over time. Its safety profile aligns with existing GLP-1 therapies, though long-term data are still being studied.

    Items Specifications
    Product Name Tirzepatide
    CAS No. 2023788-19-2
    Purity >99%
    MOQ 10vials


      Company Detail

    Fuzhou Kangyu Technology Co., Ltd is a time-honored enterprise with a long history of establishment, standing firm in the industry through years of steady development and gaining a reputation for reliability. As a professional player in the field, we mainly engage in peptide products, which have been marketed globally, winning the trust and recognition of customers from various countries and regions.
    We have long-term cooperative factories with mature production systems and advanced equipment, which lays a solid foundation for our stable supply. Relying on this strong industrial chain support, we ensure timely, stable and reliable supply, and can achieve fast delivery, effectively meeting the urgent needs of customers for products.
    Moreover, our peptide products boast mature technology, which is the result of continuous research, development and optimization over the years, ensuring excellent product quality. While maintaining high-quality standards, we also offer preferential prices, striving to bring the best value to our global clients. It is this combination of stability, efficiency, quality, and affordability that has made us a trusted partner in the peptide product market worldwide.
    Fuzhou Kangyu Technology Co., Ltd has a long history since its establishment. It has developed steadily over the years and is reliable. The company mainly engages in peptide products, which are sold worldwide. It has its own cooperative factories, ensuring timely, stable and reliable supply, fast delivery speed, mature product technology and favorable prices. 



      Shop API Weight loss product: Tirzepatide raw powder,Door-to-Door Delivery-Detailed Image 1 Shop API Weight loss product: Tirzepatide raw powder,Door-to-Door Delivery-Detailed Image 2 Shop API Weight loss product: Tirzepatide raw powder,Door-to-Door Delivery-Detailed Image 3 Shop API Weight loss product: Tirzepatide raw powder,Door-to-Door Delivery-Detailed Image 4 Shop API Weight loss product: Tirzepatide raw powder,Door-to-Door Delivery-Detailed Image 5 Shop API Weight loss product: Tirzepatide raw powder,Door-to-Door Delivery-Detailed Image 6 


    ECHEMI Editorial Reference

    Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.

    Basic Info
    Product Name:

    Tirzepatide

    Other Name:

    LY3298176;

    CAS No.:

    2023788-19-2

    Molecular Formula:

    C225H348N48O68

    Molecular Weight:

    4813

    EC Number:

    200-001-8

    Categories:

    Polypeptide

    Characteristics
    Appearance:

    White to off-white

    Research
    Class:

    Dual agonist — GIPR, GLP-1R

    Status:

    FDA-approved (Mounjaro / Zepbound)

    Mechanism:

    Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. A 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding for extended half-life (~5 days). Selectively activates both GIPR and GLP-1R signaling pathways.

    EC50 (Human GLP1R):

    0.934 nM

    EC50 (Human GIPR):

    0.0224 nM

    Source:

    Frias JP, et al. N Engl J Med. 2021;385(6):503-515.DOI

    FDA:

    Mounjaro, Zepbound (approved 2022-05-13)

    References
    ChEMBL:

    CHEMBL4297839

    DrugBank:

    DB15171

    KEGG DRUG:

    D11360

    PubChem:

    PubChem

    Disclaimer:

    Tirzepatide is approved as a prescription medicine (Mounjaro, Zepbound) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Semaglutide,Retatrutide,Nad+,Tirzepatide

    Location:

    Unit 1207, Lift 1, Office Building A2, Wanda Plaza, No. 8 Aojiang Road, Taijiang District, Fuzhou City, Fujian Province

    Payment Terms:

    100% TT in advance

    Average lead Time:

    1 days

    Total Annual Revenue:

    $1 million-$2.5 million

    Total Employees:

    11-50

    Year of Establishment:

    2024

    Company Certificates
    • Fuzhou Kangyu Technology Co., Ltd.business license business license

    Fuzhou Kangyu Technology Co., Ltd is a time-honored enterprise with a long history of establishment, standing firm in the industry through years of steady development and gaining a reputation for reliability. As a professional player in the field, we mainly engage in peptide products, which have been marketed globally, winning the trust and recognition of customers from various countries and regions.

    We have long-term cooperative factories with mature production systems and advanced equipment, which lays a solid foundation for our stable supply. Relying on this strong industrial chain support, we ensure timely, stable and reliable supply, and can achieve fast delivery, effectively meeting the urgent needs of customers for products.

    Moreover, our peptide products boast mature technology, which is the result of continuous research, development and optimization over the years, ensuring excellent product quality. While maintaining high-quality standards, we also offer preferential prices, striving to bring the best value to our global clients. It is this combination of stability, efficiency, quality, and affordability that has made us a trusted partner in the peptide product market worldwide.

    Fuzhou Kangyu Technology Co., Ltd has a long history since its establishment. It has developed steadily over the years and is reliable. The company mainly engages in peptide products, which are sold worldwide. It has its own cooperative factories, ensuring timely, stable and reliable supply, fast delivery speed, mature product technology and favorable prices.

  • Inquiry History
    2097 Inquiries
    Country Product Purchase Quantity Date Posted
    United States

    2023788-19-2 in unlabeled vials 10, 15 and 30 mg

    10  Feb 14, 2024
    United States

    Peptide drug GLP-1 Agonists Tirzepatide CAS 2023788-19-2 Weight loss 399 Inquiries

    10 MG Apr 3, 2024
    United States

    Tirzepatide Raw Powder Weight Loss Peptides CAS No 2023788-19-2 Tirzepatide Injection Peptides

    2 MT Dec 13, 2025
    Brazil

    2023788-19-2

    20 PCS Sep 12, 2026
    Hongkong, China

    2023788-19-2

    1 KG Aug 13, 2026
    Germany

    2023788-19-2

    1 MG Jun 18, 2026
    United States

    2023788-19-2 Retatrutide

    1 G Sep 22, 2023
    United States

    2023788-19-2 Trizepatide

    10 MT Oct 29, 2023
    United States

    Tirzepatide 2023788-19-2

    2  Feb 19, 2024
    United States

    Tirzepatide 2023788-19-2

    10 G Oct 31, 2023
    United States

    Trizepatide 2023788-19-2 Raw Material LY3298176 Tirzepatide powder

    1  Dec 2, 2025
    United States

    Peptide drug GLP-1 Agonists Tirzepatide CAS 2023788-19-2 Weight loss

    2 KG Oct 20, 2023
    United States

    Fat Burning Peptides Tirzepatide 10mg/Vial 15mg/Vial Tirzepatide CAS: 2023788-19-2

    1 MT Jan 25, 2024
    United States

    Pharmacy Grade CAS 2023788-19-2 Tirzepatide 99% White powder Tirzepatide

    1 MT Oct 20, 2023
    United States

    supply Tirzepatide Safe Material Shipping Trizepatide 2023788-19-2 Raw Tirzepatide powder

    10 MG Apr 4, 2024
    Kenya

    Janoshik Test Tirzepatide 99% White powder High Quality Tirzepatide Weight loss CAS 2023788-19-2

    30 MG Dec 26, 2025
    United States

    Ex-factory price tirzepatide T30 10vials 30mg kit cas 2023788-19-2 for weight loss peptide

    10  Dec 30, 2024
    United Kingdom

    Manufacturer supply high quality hot sale lowest price Tirzepatide CAS NO,2023788-19-2 99% powder 2023788-19-2 Claire

    100 G Nov 4, 2023
    Canada

    99.9% Purity GLP-1 Injection Weight Loss Peptides Liraglutide Retatrutide Tirzepatide Semaglutide 5mg 10mg CAS 2023788-19-2

    2 MT Oct 22, 2023
    United Kingdom

    tirzepatide

    10 MG Oct 21, 2025
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.